Overview

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving melphalan together with panobinostat may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of melphalan when given together with panobinostat in treating patients with recurrent multiple myeloma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Oncotherapeutics
Collaborator:
Novartis
Treatments:
Melphalan
Panobinostat